Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.

Objective To report the final, cumulative, 5-year outcomes from the TAXUS ATLAS program, which studied the use of the TAXUS Liberte paclitaxel-eluting stent in de-novo coronary artery lesions. Methods TAXUS ATLAS Workhorse, Small Vessel, and Long Lesion are nonrandomized studies comparing TAXUS Liberte (N = 871), TAXUS Liberte 2.25 mm (N = 261), and TAXUS Liberte 38 mm (N = 150) stents, respectively, with case-matched TAXUS Express historical controls. Results In the unadjusted analysis, TAXUS Liberte showed comparable 5-year rates of major adverse cardiac events (27.1% TAXUS Express vs. 26.2% TAXUS Liberte, P = 0.70) in workhorse lesions and greater 5-year cumulative freedom from target lesion revascularization (78.4 vs. 87.3%, P = 0.03) in small vessels. In addition, a lower periprocedural myocardial infarction rate (MI, 4.1 vs. 0.0%; P = 0.01) was observed in long lesions versus TAXUS Express. After propensity score adjustment, no statistically significant effect of TAXUS Liberte on the 5-year rates of TLR in small vessels (17.9 vs. 13.3%, P = 0.36) or MI in long lesions (9.1 vs. 7.0%, P = 0.53) was found, although the rates remained numerically lower with TAXUS Liberte Conclusion Cumulative 5-year results of the TAXUS ATLAS studies suggest that the TAXUS Liberte stent provides similar safety and effectiveness in workhorse lesions, and may provide lower revascularization rates in small vessels and lower periprocedural MI rates in long lesions compared with the TAXUS Express stent, although no statistically significant differences were found following propensity adjustment. Coron Artery Dis 24:61-68 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. Coronary Artery Disease 2013, 24:61-68